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Abstract
Objective—Abnormalities in autonomic function are posited to play a pathophysiologic role in 
menopausal hot flashes. We examined relationships between resting cardiac autonomic activity 
and hot flashes in peri- and postmenopausal women.
Methods—Autonomic function was assessed at baseline and 12 weeks among peri- and 
postmenopausal women (n=121, mean age=53) in a randomized trial of slow-paced respiration for 
hot flashes. Pre-ejection period (PEP), a marker of sympathetic activation, was measured with 
impedance cardiography. Respiratory sinus arrhythmia (RSA), a marker of parasympathetic 
activation, was measured with electrocardiography. Participants self-reported hot flash frequency 
and severity in 7-day symptom diaries. Analysis of covariance models were used to relate 
autonomic function and hot flash frequency and severity at baseline, and to relate changes in 
autonomic function to changes in hot flash frequency and severity over 12 weeks, adjusting for 
age, body mass index, and intervention assignment.
Results—PEP was not associated with hot flash frequency or severity at baseline or over 12 
weeks (P>.05 for all). In contrast, there was a trend toward greater frequency of moderate-to-
severe hot flashes with higher RSA at baseline (β=.43, p=.06), and a positive association between 
change in RSA and change in frequency of moderate-to-severe hot flashes over 12 weeks (β= .63, 
p=.04).
Conclusion—Among peri- and postmenopausal women with hot flashes, variations in hot flash 
frequency and severity were not explained by variations in resting sympathetic activation. Greater 
parasympathetic activation was associated with more frequent moderate-to-severe hot flashes, 
which may reflect increased sensitivity to perceiving hot flashes.
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Introduction
Hot flashes are reported by an estimated 70–80% of women during the menopause 
transition,1 often with a negative impact on quality of life. Despite their common occurrence 
among women in midlife, the pathophysiology of hot flashes is not clear. Hormonal changes 
play a role in the development of these symptoms, supported by the onset of hot flashes 
during the menopause and other periods of estrogen withdrawal, as well as the efficacy of 
estrogen administration in reducing or eliminating hot flashes.2 However, hormonal changes 
alone do not explain the variability in hot flash frequency, severity, and bother reported by 
women during the menopause transition, nor the fact that hot flashes are not reported by all 
women undergoing either gradual or sudden estrogen withdrawal.3
The autonomic nervous system, which regulates visceral organ function and the fight-or-
flight stress response, has been suggested to play a role in the pathophysiology of hot 
flashes.
Autonomic function is altered during hot flashes, supporting a temporal relationship that 
may relate to pathophysiology. Specifically, acute decreases in high frequency heart rate 
variability, related to parasympathetic tone,4–6 and acute increases in very low frequency and 
low frequency heart rate variability, measures related to sympathetic activation,7,8 have been 
observed during hot flash episodes.4–6 In contrast, evidence linking resting autonomic 
function to hot flashes is mixed, with some studies reporting differences in cardiac markers 
of sympathetic or parasympathetic activation among women with and without hot flashes,9 
but others finding no relationship of autonomic function to hot flash frequency10,11 or 
severity.12 Overall, interpretability of this small literature is limited by varied definitions and 
measurement of both hot flashes and markers of autonomic function, and small and 
homogenous samples in some studies. As a result, the role of both sympathetic and 
parasympathetic activation in the pathophysiology of hot flashes remains unclear.
In the current study, we aimed to gain a deeper insight into relationships between resting 
cardiac autonomic function and the frequency and severity of hot flashes. To that end, we 
examined associations between resting cardiac autonomic function and hot flash frequency 
and severity among peri- and postmenopausal women enrolled in a randomized trial of slow 
paced respiration for hot flashes.
Materials and Methods
Sample
Participants were drawn from the Menopausal Treatment Using Relaxation Exercises 
(MaTURE) trial, a parallel-group, single-blinded, randomized trial of slow-paced respiration 
versus music listening for treatment of hot flashes in peri- and postmenopausal women. 
Details of the eligibility criteria, recruitment procedures, and study design have previously 
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been reported.13 Briefly, participants were recruited from the San Francisco Bay Area 
between January 2012 and December 2014. Inclusion requirements included age of 40–59 
years, being peri- or postmenopausal, and reporting at least four hot flashes per day in a 
validated 7-day hot flash diary. Exclusion criteria included being pregnant or breastfeeding 
in the past year, and using medications with known effects on hot flashes in the previous 3 
months. Given the central role of paced respiration in the treatment trial, women with 
chronic pulmonary disease or baseline respiratory rate less than 10 breaths per minute were 
also excluded. All participants provided informed consent before randomization, and all 
procedures were approved by the institutional review board of the University of California, 
San Francisco.
Interventions
Participants were randomly assigned to either the paced respiration or music-listening 
intervention by computer algorithm. Women randomized to the paced respiration group 
received brief in-person instructions from a research coordinator on using a commercially 
available, portable guided breathing device (ReSPERATE; Intercure, Ltd.) to practice 
slowing their resting breathing rate to less than 10 breaths per minute. Participants 
randomized to the music control group were instructed on using an identical-appearing 
device re-programmed to play relaxing music rather than to guide breathing. Participants in 
both groups were instructed to use their assigned device for a minimum of 15 minutes per 
day for 12 weeks. Although participants were aware of their assigned intervention, study 
staff responsible for abstracting and scoring outcome data (including data on autonomic 
function and hot flashes) were blinded to intervention assignment.
Measures
To provide data on resting cardiac autonomic function, participants underwent impedance 
cardiography and electrocardiography to obtain measures of pre-ejection period (PEP) and 
respiratory sinus arrhythmia (RSA). PEP, the time period from the start of cardiac 
ventricular depolarization to ejection of blood from the ventricles, is a measure of cardiac 
contractility that has been shown to provide a pure measure of cardiac sympathetic activity 
without vagal influence.14 RSA, the degree to which heart rate accelerates and decelerates 
during the respiratory cycle, provides an indication of the amount of influence of the cardiac 
vagus nerve. It is an established marker of parasympathetic activity, based on autonomic 
blockade studies showing that heart rate variability in the high frequency range is influenced 
only by vagal, not sympathetic, influences on the heart.14–16
Measures of PEP and RSA were obtained during laboratory visits at baseline (prior to 
intervention assignment) and after 12 weeks. According to standard protocols, participants 
were outfitted with electrodes by trained study staff, and then asked to sit still, relax, and 
view a neutral nature documentary video for a 10-minute period while resting measurements 
were obtained. For impedance cardiography measurements, four tetrapolar electrode bands 
were attached to the neck and torso of each participant while in a seated position. A constant 
current of 4 mAmp was sent to the outer and inner bands, while resistance to the current was 
measured to estimate basal impedance and blood flow through the heart. 
Electrocardiography was obtained with two spot electrode sensors placed below the right 
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clavicle and below the left breast.17 All signals were integrated and stored using a Biopac 
MP150 data acquisition system (Biopac Systems, Inc.). To minimize measurement error, 
participants were asked to refrain from drinking alcohol, smoking, or using any other form 
of tobacco for at least 24 hours before measurements were obtained.
Trained research assistants visually inspected all waveforms off-line and edited and scored 
the data in one-minute bins for each of the minutes of the experiment using Mindware 
software (HRV 3.0, IMP 3.0). Following standard procedures,18 Mindware software 
(Mindware Technologies, Ltd) was used to calculate average PEP (in milliseconds) by 
examining the time between ventricular depolarization (assessed by electrocardiogram 
output) and the B point of the dZ/dt wave indicating the opening of the aortic valve 
(measured by impedance cardiography). RSA was estimated with an algorithm that uses a 4 
Hz time series to interpolate the interbeat interval,19 and a second order polynomial was 
applied to minimize non-stationary trends. A random twenty percent of the data were 
selected to be re-scored to determine reliability, which exceeded 95%.
Hot flash frequency and severity were assessed at baseline and 12 weeks using a 7-day self-
report diary, modeled after a diary that has been validated and administered in multiple prior 
clinical trials of interventions for menopause symptoms.20 Participants were asked to record 
each hot flash they experienced and rate its severity as 1/mild: sensation of heat without 
sweating; 2/moderate: sensation of heat with sweating, able to continue activity; 3/severe: 
sensation of heat with sweating, causing cessation of activity, following the FDA guidelines 
for defining hot flash severity.21 To promote accurate reporting, the diary was designed to be 
small and portable, so that participants could carry it with them during the day and keep it 
by their bedside at night.
Participants also completed structured-item questionnaires to assess age, race/ethnicity, 
relationship status, parity, history of hysterectomy and oophorectomy, educational status, 
smoking history, alcohol use, and past use of medications to treat hot flashes. Body mass 
index (BMI; kg/m2) was calculated from height and weight measured by trained study staff 
during the baseline visit.
Statistical Analyses
Demographic and clinical characteristics of participants who provided cardiac autonomic 
data were examined using descriptive statistics, and logistic regression models were used to 
assess differences in participant characteristics between intervention groups at baseline. 
Treatment effect was evaluated using linear regression models of change in autonomic 
measures adjusting for baseline value, as well as age and BMI.
Multivariable models were then developed to assess relationships between cardiac 
autonomic markers (PEP and RSA) and hot flash measures in the combined participant 
sample. For assessment of hot flashes, analyses focused on two outcomes: 1) average 
frequency of any hot flashes, and 2) average frequency of hot flashes that were rated by the 
participant as being “moderate” or “severe”. ANCOVA models were used to simultaneously 
assess baseline associations between autonomic markers and hot flashes, and associations 
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between within-person changes in autonomic markers and within-person changes in hot 
flash outcomes over 12 weeks.
Outcomes were transformed due to evidence of non-normality detected in the distribution of 
outcomes in visual inspection of density plots. All models were adjusted for age and BMI 
given that past research has indicated that both of these variables are associated with both 
resting cardiac autonomic function and hot flashes.22–24 Analyses were also adjusted for 
intervention assignment after confirmation that there were no significant interactions with 
intervention group. All statistical analyses were performed using SAS 9.4 (Cary, North 
Carolina).
Results
Baseline Participant Characteristics
Of the 123 participants randomized in the MaTURE trial, 121 contributed data on cardiac 
autonomic function at either baseline or 12 weeks and were included in baseline analyses. 
The sample was 58.7% white, with a mean age of 53.4 (SD 3.4). The majority of 
participants were naturally peri- or postmenopausal (32.7% and 54.5%, respectively). Over 
half were overweight or obese (mean BMI=26.5, SD 5.5) (table 1). After 12 weeks of 
follow-up, 89% (N=55) of women retained in the paced respiration group and 88% (N=52) 
retained in the music-listening group were confirmed to have completed at least 6 practice 
sessions per week (p=.98). In both groups, average practice time exceeded 15 minutes per 
day at 12 weeks (p=0.87).
Baseline and 12-Week Changes in Cardiac Autonomic Function
Complete data at baseline or 12 weeks was available for 118 women for PEP analyses, and 
119 women for RSA analyses. There were no significant differences in resting autonomic 
measures (PEP, RSA) between the paced respiration and music control groups at baseline. 
No significant differences between groups in changes of autonomic measures from baseline 
to 12 weeks were observed. Additionally, no significant within-group changes in autonomic 
measures from baseline to 12 weeks were observed in either group (table 2).
Associations between Cardiac Autonomic Function and Hot Flashes
Complete data at baseline and 12 weeks was available for 74 women for PEP analyses, and 
81women for RSA analyses. In ANCOVA models, no significant associations between PEP 
and hot flash measures were observed. There were also no significant associations between 
within-person change in PEP and within-person changes in hot flash outcomes from baseline 
to 12 weeks. In contrast, there was a trend toward higher RSA among participants with more 
frequent moderate-to-severe hot flashes at baseline. Additionally, within-person change in 
RSA was positively associated with within-person change frequency of moderate-to-severe 
hot flashes over 12 weeks, such that increased RSA was associated with more severe hot 
flashes over time (β= .63, p=.04) (Table 3).
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Discussion
These findings from a large and diverse sample of peri- and postmenopausal women provide 
new evidence to evaluate relationships between autonomic function and hot flashes. 
Contrary to expectations, cardiac sympathetic activation as assessed by PEP was not 
significantly associated with hot flash frequency or severity at any timepoint. In contrast, 
there was a trend toward more frequency moderate-to-severe hot flashes among women with 
greater parasympathetic activation as reflected by RSA at baseline, and change in 
parasympathetic activation was positively associated with change in frequency of moderate-
to-severe hot flashes over 12 weeks.
The theory that abnormal sympathetic autonomic function causes hot flashes7,25 has driven 
research into treatment strategies that focus on reducing excess sympathetic tone. However, 
prior research on the relationship of sympathetic function and hot flash frequency or severity 
has yielded mixed results. Two previous studies have reported increases in sympathetic 
activation estimated by very low and low frequency heart rate variability during 
physiologically measured hot flash episodes,7,8 suggesting that sympathetic activation 
occurs acutely during the brief experience of a hot flash. Other research has also reported 
greater basal sympathetic activation estimated by low frequency heart rate variability10 or 
the ratio of low and high frequency heart rate variability11 among women with hot flashes 
compared to those without hot flashes. Subsequently, an analysis of similar heart rate 
variability measurements in a recent, large, multicenter hot flash trial network found that 
these measures did not differentiate hot flash experience or intensity among women with hot 
flashes at baseline, nor were they correlated with changes in hot flashes in response to 
treatment.12 Nevertheless, all of the above studies were limited by reliance on measures that 
are not pure markers of sympathetic activity.
Our study findings using resting PEP as a pure measure of cardiac sympathetic activation do 
not support the hypothesis that sympathetic activation is a major determinant of women’s 
experience of hot flashes, given that PEP was unrelated to the frequency or severity of self-
reported hot flashes. However, our research may have been limited by the fact that all 
women taking part in the MaTURE had frequent hot flashes per day at baseline, although 
some experienced resolution over the 12 week period. Even if differences in sympathetic 
activation do not contribute to variation in hot flash frequency or severity among women 
with a recent history of hot flashes, it is possible that they may contribute to differences in 
the onset or occurrence of hot flashes in women with hot flashes compared to those without 
hot flashes.
Abnormal parasympathetic function has also been implicated in the pathophysiology of hot 
flashes. Several previous studies have documented acute decreases in parasympathetic 
activity during physiologically measured and self-reported hot flash episodes, suggesting 
acute vagal withdrawal during hot flashes.4–6 However, prior research has not found 
relationships between resting parasympathetic activity and hot flash frequency or severity 
among midlife women.9,12 In the current study, there was evidence of an association 
between cardiac parasympathetic activation and frequency or severity of hot flashes at 
baseline and over 12 weeks. These findings are intriguing in that they suggest that resting 
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parasympathetic activation play a more important role in women’s experience of hot flashes 
than has previously been suggested.
The relationship between parasympathetic activation and hot flashes observed in this study 
is at odds with other research indicating that decreased parasympathetic function tends to be 
a vulnerability factor for other adverse physical and mental health outcomes. It is known that 
lower levels of heart rate variability can impair the ability to adapt to stressors, for example, 
and are associated with more susceptibility to hypotension, sudden death, and mortality 
following myocardial infarction.26 Moreover, low levels of RSA have been documented 
across a range of psychopathologies often associated with hot flashes, including anxiety27,28 
and depressive symptoms.29 However, increased RSA levels are also known to be associated 
with greater interoceptive awareness, or increased sensitivity to bodily states.30 A 
relationship between higher resting parasympathetic activation and more frequent self-
reported hot flashes may therefore reflect greater sensitivity to detecting or perceiving hot 
flashes, resulting from greater interoception among these women. Future research may 
benefit from investigating how individual differences in interoception mediate the link 
between RSA levels and the subjective experience or reporting of hot flashes.
Of note, the device-guided paced respiration intervention used in this study did not produce 
significant changes in cardiac sympathetic or parasympathetic activation over 12 weeks, 
compared to the music-listening control intervention. While acute effects of paced 
respiration on cardiac autonomic function have been demonstrated in laboratory studies,31,32 
prior research has not yielded consistent evidence of a sustained effect of paced respiration 
interventions on cardiovascular autonomic function.33 In the few randomized controlled 
trials with a similar design to the current study, equivalent autonomic markers were not 
assessed, and samples were comprised of men and women with hypertension and/or diabetes 
mellitus. It therefore remains unclear whether regular practice of paced respiration causes 
long-term changes in cardiac autonomic function, at least when practiced using this type of 
portable guided-breathing device.
This study has limitations that warrant mention. First, while hot flashes were assessed using 
detailed symptom diaries, this study did not include physiological measures of hot flash-
related vasodilation or sweating to provide additional insight into the biological 
underpinnings of hot flashes and autonomic function. Exploration of the relationship 
between both physiologic and self-reported measures of hot flash experience and basal 
parasympathetic function may be warranted in future research. Second, frequent daily hot 
flashes were required for eligibility, and relationships between autonomic function and hot 
flashes may differ for less symptomatic women. As there was no control arm in this study, 
we cannot determine how relationships between autonomic function and hot flashes may 
differ over time in the absence of an active intervention. Additionally, participants had to be 
willing and able to commit to the behavioral study interventions over 12 weeks and to 
abstain from using other clinical treatments for hot flashes. Overall, generalizability of these 
findings may be limited due to these requirements. Further, significant mean associations 
were not seen in all analytic models, and findings may have been spurious in the context of 
multiple comparisons.
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Despite these limitations, this study had considerable strengths. Multiple measures of 
autonomic function were measured in a rigorously controlled setting. Retention rates were 
high throughout the observed period. Hot flashes were assessed by self-report diaries over 
seven days, which offers more reliability and limited retrospective recall bias than 
retrospective recall at one point in time. Further, multiple important aspects of hot flash 
experience, including frequency and severity, were assessed at each time point. The 
participant sample was also ethnically diverse and representative of women from across the 
menopause transition.
Conclusions
In this large sample of peri- and postmenopausal women enrolled in a behavioral paced 
respiration intervention trial for hot flashes, resting cardiac sympathetic activation was not 
associated with greater hot flash frequency or severity. In contrast, cardiac parasympathetic 
activation was associated with greater overall hot flash frequency and severity. These 
findings point to potentially more complex relationships between basal cardiac autonomic 
function and hot flashes than has previously been proposed, such as the possibility that 
increased resting parasympathetic tone may be associated with greater interoception 
affecting women’s perception of hot flashes.
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Table 1
Baseline characteristics of participants included in cardiac autonomic function analyses (n=121)
Paced
respiration
(N=62)
Music listening
(N=59)
Total Sample
(N=121) p-value
Age in years (mean, SD) 53.1 (3.4) 53.7 (3.4) 53.4 (3.4) 0.29
Race (number, %)
  White 38 (61.3) 33 (55.9) 71 (58.7) 0.55
  Black/African-American 13 (21.0) 16 (27.1) 29 (24.0) 0.43
  Latina/Hispanic 2 (3.2) 4 (6.8) 6 (5.0) 0.37
  Asian/Asian-American 12 (19.4) 8 (13.6) 20 (16.5) 0.39
  Other/unspecified 5 (8.1) 5 (8.5) 10 (8.3) 0.94
Education (number, %)
  College+ graduate 56 (90.3) 54 (91.5) 110 (90.9) 0.82
Relationship status (number, %)
  Married or in a significant
relationship 42 (67.7) 29 (49.2) 71 (58.7) 0.04
  Single/widowed/divorced 20 (32.3) 30 (50.8) 50 (41.3)
Parity
Live births (mean, SD) 1.31 (1.3) 1.31 (1.6) 1.31 (1.4) 0.63
Medication Use (number, %)
  Beta-blocker 8 (6.8) 7 (6.3) 15 (6.6) 0.86
  Sympathomimetic 2 (1.7) 3 (2.7) 5 (2.2) 0.62
  Anti-cholinergic 14 (12.0) 18 (16.1) 32 (14.0) 0.37
  Nicotinic antagonist 2 (1.7) 0 (0) 2 (0.9) 0.17
Menopausal history (number, %)
  Hysterectomy 6 (9.7) 7 (11.9) 13 (10.7) 0.70
  Bilateral oophorectomy 1 (1.6) 2 (3.4) 3 (2.5) 0.53
  Naturally postmenopausala 26 (48.1) 34 (60.7) 60 (54.5) 0.19
  Perimenopausalb 21 (38.9) 15 (26.8) 36 (32.7) 0.18
Past use of hot flash treatments
(number, %)
  Hormones (Estrogen) 7 (11.3) 7 (11.9) 14 (11.6) 0.92
  Gabapentin 0 (0.0) 2 (3.4) 2 (1.7) 0.14
  Alternative Therapies 13 (21.0) 19 (32.2) 32 (26.4) 0.16
Body Mass Index (number, %)
  < 25 kg/m2 25 (40.3) 29 (49.2) 54 (44.6) 0.44
  25 to <30 kg/m2 21 (33.9) 14 (23.7) 35 (28.9)
  >= 30 kg/m2 16 (25.8) 16 (27.1) 32 (26.4)
Vital signs (mean, SD)
  Systolic blood pressure (mmHg) 122.31 (19.7) 118.85 (14.2) 120.62 (17.2) 0.35
  Diastolic blood pressure(mmHg) 77.23 (10.9) 76.37 (11.9) 76.81 (11.3) 0.57
  Heart rate (bpm) 70.42 (10.4) 67.97 (11.5) 69.22 (11.0) 0.13
  Respiratory rate (breaths/pm) 13.60 (2.5) 13.97 (3.2) 13.78 (2.8) 0.66
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Paced
respiration
(N=62)
Music listening
(N=59)
Total Sample
(N=121) p-value
Health behaviors (number, %)
  Current cigarette smoker 4 (6.6) 8 (13.8) 12 (10.1) 0.19
  Alcohol use on ≥ 5 day/week 8 (12.9) 6 (10.2) 14 (11.6) 0.64
Cardiac autonomic measures
(mean, SD)
  PEP (ms) during movie 121.7 (13.7) 121.7 (13.4) 121.3 (13.5) 0.86
  RSA (ms2) during movie 5.56 (1.2) 5.20 (1.3) 5.38 (1.3) 0.23
aAll women without a history of hysterectomy or bilateral oophorectomy who report no menstrual period for 1 year were considered naturally 
postmenopausal.
bWomen without a history of hysterectomy or bilateral oophorectomy who report a menstrual period within the past year were considered 
perimenopausal.
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Table 3
Adjusted associations between cardiac autonomic measures and hot flash outcomes among all participants
Baseline Levels
Frequency of any hot
flashes
Frequency of moderate-to-severe
hot flashes
Coefficient p-value Coefficient p-value
Pre-ejection period (ms) −.01 .69 −.01 .86
Respiratory sinus
arrhythmia (ms2)
.34 .21 .43 .06
12-Week Change
Frequency of any hot
flashes
Frequency of moderate-to-severe
hot flashes
Coefficient p-value Coefficient p-value
Pre-ejection period (ms) −.00 .99 .00 .76
Respiratory sinus
arrhythmia (ms2)
.26 .44 .63 .04
ANCOVA with between-person associations at baseline and within-person changes in autonomic markers and hot flashes from baseline to 12 
weeks. All models adjusted by intervention assignment, age, and BMI. The number of participants included was 74 and 81 for the PEP and RSA 
models respectively.
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